Want to see FDMT full AI Analyst Report?
FDMT Stock Chart & Stats
$10.49
-$0.14(-2.20%)
At close: 4:00 PM EST
$10.49
-$0.14(-2.20%)
Day’s Range― - ―
52-Week Range$4.15 - $14.00
Previous CloseN/A
Volume165.32K
Average Volume (3M)961.38K
Market Cap
$574.52M
Enterprise Value$263.32
Total Cash (Recent Filing)$390.89M
Total Debt (Recent Filing)$20.54M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 06, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding52,276,253
10 Day Avg. Volume620,505
30 Day Avg. Volume961,376
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$31.80Price Target Upside203.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.04
Revenue Forecast (FY)$12.23M
Bulls Say, Bears Say
Bulls Say
Proprietary AAV Vector Platform4D's engineered AAV capsid platform is a durable competitive asset: it enables targeted tissue delivery across indications, supports multiple internal programs and partner licensing, and creates a scalable technology moat that can generate recurring collaboration revenue and long-term strategic partnerships.
Phase 3 Program MomentumCompleting enrollment in a second global Phase 3 materially de-risks clinical timelines and moves a lead asset toward potential regulatory milestones. This progress raises the probability of near-term pivotal data, milestone-triggered payments, and strategic partnering opportunities that support sustainable program value.
Low Leverage On Balance SheetA relatively low debt burden gives FDMT structural financial flexibility versus highly levered peers. Modest secured debt reduces immediate refinancing pressure, lowers default risk, and preserves the company's ability to pursue R&D and partner negotiations without large interest obligations crowding cash flow.
Bears Say
Sustained Cash BurnPersistent, large negative operating and free cash flow indicate the company requires ongoing external financing to sustain development. Over a multi-month horizon this increases dilution risk, heightens dependence on milestone timing, and can constrain strategic options if expected funding or partnership payments are delayed.
Continued Operating Losses And Margin InstabilityVolatile top-line performance with deeply negative margins signals the business remains pre-commercial and loss-making. Without predictable revenue streams from products or recurring royalties, profitability is unlikely in the near term, pressuring equity value and complicating long-term planning.
Senior Secured Loan CovenantsThe Hercules facility provides funding but is senior secured and includes cash, market-cap and performance covenants. These structural constraints can limit operational flexibility, risk triggering remedies if metrics slip, and complicate future financings or partnership terms if covenant tests become binding.
4D Molecular Therapeutics News
FDMT FAQ
What was 4D Molecular Therapeutics, Inc.’s price range in the past 12 months?
4D Molecular Therapeutics, Inc. lowest stock price was $4.14 and its highest was $14.00 in the past 12 months.
What is 4D Molecular Therapeutics, Inc.’s market cap?
4D Molecular Therapeutics, Inc.’s market cap is $574.52M.
When is 4D Molecular Therapeutics, Inc.’s upcoming earnings report date?
4D Molecular Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were 4D Molecular Therapeutics, Inc.’s earnings last quarter?
4D Molecular Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.996 by -$0.014.
Is 4D Molecular Therapeutics, Inc. overvalued?
According to Wall Street analysts 4D Molecular Therapeutics, Inc.’s price is currently Undervalued.
Does 4D Molecular Therapeutics, Inc. pay dividends?
4D Molecular Therapeutics, Inc. does not currently pay dividends.
What is 4D Molecular Therapeutics, Inc.’s EPS estimate?
4D Molecular Therapeutics, Inc.’s EPS estimate is -1.01.
How many shares outstanding does 4D Molecular Therapeutics, Inc. have?
4D Molecular Therapeutics, Inc. has 52,276,253 shares outstanding.
What happened to 4D Molecular Therapeutics, Inc.’s price movement after its last earnings report?
4D Molecular Therapeutics, Inc. reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.996. Following the earnings report the stock price went up 2.115%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics, Inc.?
Currently, no hedge funds are holding shares in FDMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4D Molecular Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.80 (203.15% Upside)
$31.80 (203.15% Upside)
Blogger Sentiment
Bullish
FDMT Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $117.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
152.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.55%
Trailing 12-Months
Company Description
4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
FDMT Stock 12 Month Forecast
Average Price Target
$31.80
▲(203.15% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Design Therapeutics
―
Immuneering
―
Aura Biosciences Inc
―
Ownership Overview
2.18% Insiders
13.18% Mutual Funds
0.16% Other Institutional Investors
66.86% Public Companies and
Individual Investors